The New England Journal of Medicine published research results today from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).
Le Bonheur Children's Hospital and the University of Tennessee Health Science Center researcher Infectious Disease Specialist John DeVincenzo, M.D., is lead author of this study.
RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits, according to the Centers for Disease Control and Prevention (CDC). DeVincenzo and his fellow researchers have been part of virtually every experimental therapeautic advancement, developmental pathway and antiviral therapy created to tackle the virus in the past 15 years. Learn more about his research at lebonheur.org/promise.